Home » Topics » Ocular, BioWorld Science

Ocular, BioWorld Science
RSS

BioLon receives FDA approval

July 23, 1998

FDA grants fast track status to Miravant's Purlytin

July 10, 1998

Allergan signs collaborative agreement with Santen for brimonidine

July 10, 1998

Clinical update on Advanced Corneal Systems' Vitrase

July 6, 1998

Gene linked to inherited glaucoma

July 6, 1998

Miravant and Pharmacia & Upjohn amend Purlytin agreements

June 15, 1998

Asahi Glass, Santen develop ophthalmic agents with good safety

June 12, 1998

Latanoprost compared to unoprostone in monkeys with glaucoma

June 10, 1998

CAT's monoclonal antibody progresses in ophthalmic clinical trials

June 8, 1998

Advanced Corneal System seeks Vitrase approval in Mexico

June 4, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.